This site is intended for Healthcare Professionals only. if you are a member of the general public, click here
Pinch & zoom to explore
No dose adjustment is necessary for patients with renal impairment. Patients with mild or moderate chronic hepatic impairment (Child-Pugh class A or B) are recommended to complete the 7-day dose escalation regimen, and then take 0.92 mg once every other day. ZEPOSIA was not evaluated in patients with severe hepatic impairment. Therefore, patients with severe hepatic impairment (Child-Pugh class C) must not be treated with ZEPOSIA.1
*First dose, hourly monitoring over a 6-hour period is recommended for patients with a resting heart rate <55 bpm, second-degree (Mobitz type I) AV block or a history of myocardial infarction or heart failure. These patients should be monitored for signs and symptoms of bradycardia.1
Please refer to the ZEPOSIA Summary of Product Characteristics for full safety information.
AV: atrioventricular; bpm: beats per minute; ECG, electrocardiogram; VZV, varicella-zoster virus